Pharmaceutical

Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

TORONTO, ON / ACCESSWIRE / February 6, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...

Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms

Updated Chemistry, Manufacturing, and Controls and Stability Test fulfill Ainos' development objectivesResolving the identified deficiencies will accelerate the timeline for...

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (a $498...

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy

Canadian patients living with this ultra-rare condition welcome this new treatment optionBOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Chiesi Global...

Uncle Bud’s to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

CBD Body Revive Spray All Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class, UltraShear-processed Nano CBD Multi-Patented Nanoemulsification Platform Enables...

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results...

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

GE HealthCare receives FDA clearance for expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks....

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

GE HealthCare receives FDA clearance for expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks....

error: Content is protected !!